Logo Image

Deepak Adhikari

Articles by Deepak Adhikari

75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings

ByMarvin Nguyen,Ruchit Shah,Anagha Gogate,Deepak Adhikari,Lisa Herms,Heather Neuhalfen,Aaron Peevyhouse,Scott Cole,Sibel Blau,Mark Walker

T-DXd demonstrated a real-world overall response rate of 56.3%, median rwPFS of 7.4 months, and 12-month OS of 62% in patients with HER2-low metastatic breast cancer treated across US community oncology settings.

76 Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices

ByMark Walker,Marvin Nguyen,Ruchit Shah,Anagha Gogate,Deepak Adhikari,Lisa Herms,Heather Neuhalfen,Aaron Peevyhouse,Scott Cole,Sibel Blau

In a real-world cohort of 300 patients with HER2-low metastatic breast cancer, T-DXd demonstrated a safety profile consistent with DESTINY-Breast04 in community oncology settings, with ILD/pneumonitis in 10% and toxicity-related discontinuation in 15%.

Latest Updated Articles